SEOUL, Oct 26 (Reuters) - South Korea granted emergency use
approval for Moderna's COVID-19 vaccine produced by
South Korean drugmaker Samsung BioLogics, the health
ministry said on Tuesday.
Moderna has agreed to distribute 2.44 million doses of the
shots produced by Samsung to South Korea after Samsung's
COVID-19 vaccine facility on Monday obtained Good Manufacturing
Practice (GMP) certification from the drug safety ministry.
Samsung entered into a "fill and finish https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-south-korea-sign-production-deal-mrna-vaccines-2021-05-22
" deal with Moderna in May. This type of contract involves
putting vaccines into vials or syringes, sealing them and
packaging them up for shipping, but not making the vaccine
The plant has yet to win approval from the U.S. and European
regulators to have the shots shipped outside the country,
In May https://www.reuters.com/world/asia-pacific/south-koreas-moon-be-second-leader-second-asian-welcomed-by-biden-2021-05-21,
the U.S. President Joe Biden said he and South Korean President
Moon Jae-in had agreed on a comprehensive partnership on
South Korea said the Moderna shots produced by Samsung will
be widely used in the current quarter, including as booster
shots for high-risk people.
(Reporting by Sangmi Cha; Editing by Lincoln Feast.)